• 1
    Llovet JM,Burroughs A,Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 190717.
  • 2
    El-Serag HB,Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999; 340: 74550.
  • 3
    Bruix J,Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 51924.
  • 4
    Gralow J,Ozols RF,Bajorin DF,Cheson BD,Sandler HM,Winer EP,Bonner J,Demetri GD,Curran WJ,Ganz PA,Kramer BS,Kris MG, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 31325.
  • 5
    Onji M,Akbar F,Horiike N. Dendritic cell-based immunotherapy for hepatocellular carcinoma. J Gastroenterol 2001; 36: 7947.
  • 6
    Ladhams A,Schmidt C,Sing G,Butterworth L,Fielding G,Tesar P,Strong R,Leggett B,Powell L,Maddern G,Ellem K,Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroen Hepatol 2002; 17: 88996.
  • 7
    Takayama T,Sekine T,Makuuchi M,Yamasaki S,Kosuge T,Yamamoto J,Shimada K,Sakamoto M,Hirohashi S,Ohashi Y,Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 8027.
  • 8
    Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 26374.
  • 9
    Woo EY,Chu CS,Goletz TJ,Schlienger K,Yeh H,Coukos G,Rubin SC,Kaiser LR,June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 476672.
  • 10
    Curiel TJ,Coukos G,Zou L,Alvarez X,Cheng P,Mottram P,Evdemon-Hogan M,Conejo-Garcia JR,Zhang L,Burow M,Zhu Y,Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 9429.
  • 11
    Kono K,Kawaida H,Takahashi A,Sugai H,Mimura K,Miyagawa N,Omata H,Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 106471.
  • 12
    Shimizu J,Yamazaki S,Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 521118.
  • 13
    Steitz J,Bruck J,Lenz J,Knop J,Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced. CD8(+) T-cell-dependent immune defense of. B16 melanoma. Cancer Res 2001; 61: 86436.
  • 14
    Ghiringhelli F,Menard C,Puig PE,Ladoire S,Roux S,Martin F,Solary E,Le Cesne A,Zitvogel L,Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 6418.
  • 15
    Mahnke K,Schonfeld K,Fondel S,Ring S,Karakhanova S,Wiedemeyer K,Bedke T,Johnson TS,Storn V,Schallenberg S,Enk AH. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120: 272333.
  • 16
    Ormandy LA,Hillemann T,Wedemeyer H,Manns MP,Greten TF,Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 245764.
  • 17
    Unitt E,Rushbrook SM,Marshall A,Davies S,Gibbs P,Morris LS,Coleman N,Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005; 41: 72230.
  • 18
    Yang XH,Yamagiwa S,Ichida T,Matsuda Y,Sugahara S,Watanabe H,Sato Y,Abo T,Horwitz DA,Aoyagi Y. Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45: 25462.
  • 19
    Fu J,Xu D,Liu Z,Shi M,Zhao P,Fu B,Zhang Z,Yang H,Zhang H,Zhou C,Yao J,Jin L, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 232839.
  • 20
    Kobayashi N,Hiraoka N,Yamagami W,Ojima H,Kanai Y,Kosuge T,Nakajima A,Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 90211.
  • 21
    Unitt E,Marshall A,Gelson W,Rushbrook SM,Davies S,Vowler SL,Morris LS,Coleman N,Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 24653.
  • 22
    Gao Q,Qiu SJ,Fan J,Zhou J,Wang XY,Xiao YS,Xu Y,Li YW,Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 258693.
  • 23
    Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295307.
  • 24
    Li L,Li SP,Min J,Zheng L. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 2007; 114: 3845.
  • 25
    Kuang DM,Wu Y,Chen N,Cheng J,Zhuang SM,Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007; 110: 58795.
  • 26
    Kuang DM,Zhao Q,Xu J,Yun JP,Wu C,Zheng L. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J Immunol 2008; 181: 308998.
  • 27
    Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 718.
  • 28
    Lewis CE,Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 60512.
  • 29
    Curry MP,Norris S,Golden-Mason L,Doherty DG,Deignan T,Collins C,Traynor O,McEntee GP,Hegarty JE,O'Farrelly C. Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterization. J Immunol Methods 2000; 242: 2131.
  • 30
    Montosi G,Corradini E,Garuti C,Barelli S,Recalcati S,Cairo G,Valli L,Pignatti E,Vecchi C,Ferrara F,Pietrangelo A. Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology 2005; 41: 54552.
  • 31
    Jiang W,Sun R,Wei H,Tian Z. Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc Natl Acad Sci USA 2005; 102: 1707782.
  • 32
    Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984; 2: 395428.
  • 33
    Randolph DA,Fathman CG. CD4+CD25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57: 381402.
  • 34
    Walker MR,Kasprowicz DJ,Gersuk VH,Benard A,Van Landeghen M,Buckner JH,Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25 T cells. J Clin Invest 2003; 112: 143743.
  • 35
    Pillai V,Karandikar NJ. Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett 2007; 114: 915.
  • 36
    Ai WZ,Hou JZ,Zeiser R,Czerwinski D,Negrin RS,Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009; 124: 23944.
  • 37
    Ghiringhelli F,Puig PE,Roux S,Parcellier A,Schmitt E,Solary E,Kroemer G,Martin F,Chauffert B,Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 91929.
  • 38
    Groux H,O'Garra A,Bigler M,Rouleau M,Antonenko S,de Vries JE,Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 73742.
  • 39
    Kryczek I,Wei S,Zou L,Zhu G,Mottram P,Xu H,Chen L,Zou W. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177: 404.
  • 40
    Hoechst B,Ormandy LA,Ballmaier M,Lehner F,Kruger C,Manns MP,Greten TF,Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 23443.